(Q39438220)

12 September 2017

title

Lansoprazole in the treatment of heartburn in patients without erosive oesophagitis (English)

1 reference

12 September 2017

0 references

Richter JE

1

1 reference

12 September 2017

Kovacs TO

2

1 reference

12 September 2017

Greski-Rose PA

3

1 reference

12 September 2017

Huang section sign B

4

1 reference

12 September 2017

Fisher R

5

1 reference

12 September 2017

language of work or name

English

0 references

publication date

1 June 1999

1 reference

Alimentary Pharmacology & Therapeutics

12 September 2017

published in

1 reference

12 September 2017

volume

13

1 reference

12 September 2017

issue

6

1 reference

12 September 2017

page(s)

795-804

1 reference

Symptomatic gastroesophageal reflux: incidence and precipitating factors

12 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.1999.00558.X

The diagnosis and treatment of gastroesophageal reflux disease in a managed care environment, Suggested disease management guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.1999.00558.X

Epidemiology and natural history of gastro-oesophageal reflux disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.1999.00558.X

Patterns of Gastroesophageal Reflux in Health and Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.1999.00558.X

21 January 2018

Heartburn--the acid test

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.1999.00558.X

Optimal dose of oral omeprazole for maximal 24 hour decrease of intragastric acidity

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.1999.00558.X

Rapid symptom relief in reflux oesophagitis: a comparison of lansoprazole and omeprazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.1999.00558.X

Prevention of duodenal ulcer recurrence with 15 mg lansoprazole: a double-blind placebo-controlled study. The Lansoprazole Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.1999.00558.X

Lansoprazole 30 mg daily versus ranitidine 150 mg b.d. in the treatment of acid-related dyspepsia in general practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.1999.00558.X

10.1046/J.1365-2036.1999.00558.X

21 January 2018

Identifiers

DOI

1 reference

12 September 2017

1 reference